8-K
filed March 27, 2025, 7:59 PM ET
ticker BMEA
CIK 0001840439
leadership
confidence high
sentiment neutral
materiality 0.75
Biomea Fusion, Inc. (BMEA): Nasdaq/NYSE listing notice — Biomea Fusion CEO Thomas Butler out; Board member Mick Hitchcock named interim CEO
Biomea Fusion, Inc.
- Thomas Butler terminated as CEO, resigned as director and Chairman effective March 25, 2025.
- Michael J.M. Hitchcock (Mick) appointed interim CEO; Rainer Erdtmann named principal financial officer.
- Audit Committee now has only two members due to Hitchcock's resignation; Nasdaq cure period until March 25, 2026.
- Hitchcock receives $633,000 base salary, 50% target bonus, and options for 350,000 shares at $2.52/share.
- Press release cites positive Phase II data for icovamenib as company pursues diabetes therapy.
Key facts
Extracted from this filing and checked against the source text.
Listing & Compliance Notices
SEC 8-K Item 3.01
confidence 0.9
Biomea Fusion, Inc. received a nasdaq deficiency notice notice regarding audit committee (rules 5605(c)(2)(A), 5605(c)(4)).
- Exchange
- nasdaq
- Notice
- deficiency notice
- Deficiency
- audit committee
- Rules
- 5605(c)(2)(A), 5605(c)(4)
Exact text from the filing
March 27, 2025, Biomea Fusion, Inc. (the “Company”) notified the Nasdaq Stock Market LLC (“Nasdaq”) that the Company is not in compliance with the audit committee requirement under Nasdaq Listing Rule 5605(c)(2)(A) due to the Company having only two members on its audit committee (the “Audit Committee”) of its Board of Directors of the Company (the “Board”) solely due to a vacancy resulting from Michael (Mick) J.M. Hitchcock, Ph.D.’s resignation from the Audit Committee in connection with his appointment as interim Chief Executive Officer of the Company effective March 25, 2025. The Company ha
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Thomas Butler resigned as Chief Executive Officer at Biomea Fusion, Inc..
- Action
- resigned
- Role
- Chief Executive Officer
Exact text from the filing
The employment of Thomas Butler as Chief Executive Officer of the Company ended on March 25, 2025 (the “Effective Date”).
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Michael J. M. Hitchcock was appointed as interim Chief Executive Officer at Biomea Fusion, Inc..
- Action
- appointed
- Role
- interim Chief Executive Officer
Exact text from the filing
Dr. Hitchcock, a member of the Board, was appointed as the Company’s interim Chief Executive Officer and principal executive officer
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Thomas Butler resigned as Director and Chairman of the Board at Biomea Fusion, Inc..
- Action
- resigned
- Role
- Director and Chairman of the Board
Exact text from the filing
On the Effective Date, Mr. Butler resigned as a director and Chairman of the Board
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Rainer Erdtmann was appointed as Principal Financial Officer and Principal Accounting Officer at Biomea Fusion, Inc..
- Action
- appointed
- Role
- Principal Financial Officer and Principal Accounting Officer
Exact text from the filing
Rainer (Ramses) Erdtmann, the Company’s President, Chief Operating Officer and a member of the Board, was appointed as the Company’s principal financial officer and principal accounting officer
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.